Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > BUSINESS
BUSINESS
- Padcev/Keytruda Label Expansion Accepted for US FDA Review
October 23, 2025
- Astellas JV Aims to Bridge “Valley of Death” in Cell Therapy Manufacturing: CEO
October 22, 2025
- Krystal Launches Japan’s First DEB Therapy Vyjuvek Gel
October 22, 2025
- Japanese Drug Makers’ Domestic Sales Inch Up on Shift toward Specialty Areas: Fuji Keizai
October 22, 2025
- Sawai, Asahi Kasei Reach Settlement in Teribone Patent Suit
October 22, 2025
- Sumitomo Pharma Drops Option on FunPep’s FPP003 Peptide
October 22, 2025
- Daiichi Sankyo’s Anti-CDH6 ADC Hits Primary Goal in Global PII
October 22, 2025
- Daiichi Sankyo Unveils Dose-Escalation Data on TA-MUC1-Targeting ADC
October 22, 2025
- Taiho Secures Japan, Asian Rights to Arcus’ HIF-2α Inhibitor Casdatifan
October 21, 2025
- Santen Nabs Distribution Rights to Beovu, Lucentis in South Korea
October 21, 2025
- Chugai, Rani Therapeutics Strike Deal on Oral Antibody Drug
October 21, 2025
- Chugai to File Tecentriq for Adjuvant Bladder Cancer Use in 2026 after Positive Data
October 21, 2025
- Japan Approves Nonprescription Version of Morning-After Pill: ASKA
October 21, 2025
- Meiji Completes New Facilities to Restart Domestic Production of 6-APA
October 20, 2025
- Chiesi Japan to Expand Workforce Tenfold by 2030 on Back of New Drug Filings
October 20, 2025
- iPark, KoreaBIO Ink MOU to Fuel Japan-Korea Cooperation in Life Sciences
October 20, 2025
- Novo, JAST Join Hands to Raise Awareness of Obesity
October 20, 2025
- Taiho Bags Haihe’s PI3Kα Inhibitor Risovalisib
October 17, 2025
- Lilly Japan Teams Up with 23 Medical Societies to Strengthen Obesity Care
October 17, 2025
- Viatris Snaps Up Japan’s Aculys Pharma, Gains 2 CNS Assets
October 17, 2025
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…